GH Research PLC

NasdaqGM GHRS

GH Research PLC EPS (Diluted) for the year ending December 31, 2023: USD -0.68

GH Research PLC EPS (Diluted) is USD -0.68 for the year ending December 31, 2023, a -385.71% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

GH Research PLC EPS (Diluted) for the year ending December 31, 2022 was USD -0.14, a 22.22% change year over year.
GH Research PLC EPS (Diluted) for the year ending December 31, 2021 was USD -0.18, a -2,712.50% change year over year.
GH Research PLC EPS (Diluted) for the year ending December 31, 2020 was USD -0.01, a -45.45% change year over year.
GH Research PLC EPS (Diluted) for the year ending December 31, 2019 was USD -0.00.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGM: GHRS

GH Research PLC

CEO	Dr. Velichka Valcheva M.D.
IPO Date	June 25, 2021
Location	Ireland
Headquarters	28 Baggot Street Lower
Employees	49
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Research & Consulting

Description

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Key trends

Past 5 years